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Background
Recent experiments show that erythropoietin (EPO) plays a protective role in brain ischemia. In this condition, the EPO receptor (EPO-R) are upregulated and administration of EPO provides protection against apoptosis. It is unknown whether the EPO-R is expressed in the heart and if EPO exerts similar beneficial effects during hypoxic stress in cardiac cells. We report the first evidence that a functional EPO-R is expressed in rat cardiac tissue and EPO plays an anti-apoptotlc role. Methods First we studied the functionality of the EPO-R. by incubating rat cardiac tissue (n=4) for one hour with increasing doses EPO (control, 1CJ' U/ml, 10-l U/ml, and 1 U/ml) and measuring STAT-5 phosphorylation by Western Blotting. To further evaluate the effects of EPO, we induced low-flow ischemia (30 min at 1.7 mllmin) followed by 45 min of reperfusion in Langendorff perfused rat hearts. Four groups of hearts were used: control hearts (n =6), control healts that were perfused with EPO (0.3U/ml) (n =6), hearts subjected to low flow ischemia with EPO (n=6) and without EPO administration (n=6 after Ml. This activity, however, was not seen again at any time points after 5 minutes, except at 24 hr after Ml (89.42349 ll/pg protein). Active MMP-3 was seen in normal heart (control, 32.5e6.4) and at each time point measured except at 7 days after MI, where it decreased (12.5+3.7 vs 32.5~6.4 IlCg protein, PcO.05). However, proMMP-3 was only seen at 7 days after Ml. In conclusion, LV myocardlal MMP activity increases within minutes of Ml and early changes in hemodynamic may be the precipitating factor. Coronary arterial reocclusion following successful fibrinolysis occurs in 10 to 15% of patients despite heparin-based anticoagulant therapy. We have shown previously that unfractionated heparin (UFH) depletes endothelial cell tissue factor pathway inhibitor (TFPI), an important component of vascular thromboresistance. Because plasmin. the active enzyme generated from plasminogen by fibrinolytics is a non-specific protease, we determined its effect on endothelial cell TFPI. Conclusions: Plasmin, a non-specific protease generated in high concentrations following frbrinolytic therapy, decreases endothelial cell surface TFPI. The combined effects of UFH and plasmin may substantially impair antiprotease activity and vascular thromboresistance, contributing to coronary arterial rethrombosis. (HF) . Clinical data demonstrate that therapies which improve NO mediated vasorelaxation by modulating the renin-angiotensin-aldosterone system also decrease mortality in subjects with HF. In the Randomized Aldactone Evaluation Study, the aldosterone antagonist, sprronolactone.
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reduced mortality of HF patients. Our study was designed to determine if spironolactone improves NO mediated endothelial dependent vasorelaxation. Myocardial infarcted (Ml) adult (8.10 weeks old) Sprague Dawley rats (n=lO) in HF were treated with spironolactone (7 mgikglday) for 4 weeks. At the end of the treatment period, all animals underwent hemodynamic studies. The heart and tho-
